reflective

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing…

1 week ago

HAI Community Presents Learning Journals Inspired by the Work of Cassian Grant

New York, NY, July 17, 2025 (GLOBE NEWSWIRE) -- HAI Community, the international education platform founded by Cassian Grant, today…

4 months ago